Public Funding for Medannex Limited

‘MedAnnex is developing a novel oncology therapy based on targeting a protein known as annexin-A1, which is thought to play a role in the development of cancer. This project is a vital step in the development of an innovative cancer therapy with the potential to become a major new drug to improve patient quality of life and extend lives.’

MedAnnex is developing a new therapeutic called annexuzlimab(tm). It targets and binds to annexin-A1, a protein that occurs naturally in the human body and plays an important role in the response of the immune system to inflammation. There are well known links between inflammation and numerous major diseases including several autoimmune conditions such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. This project is a vital step in the development of annexuzlimab as an innovative therapy with the potential to become a major new drug to extend and improve lives.